EWTX
Edgewise Therapeutics Inc

539
Loading...
Loading...
News
all
press releases
Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 173% in Edgewise Therapeutics (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4d ago
News Placeholder
More News
News Placeholder
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Zacks·4mo ago
News Placeholder
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
Zacks·4mo ago
News Placeholder
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief...
Business Wire·8mo ago
News Placeholder
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43rd...
Business Wire·8mo ago
News Placeholder
US Futures Jump, Ignore Global Selloff While Focusing On Imminent Rate Cut
US Futures Jump, Ignore Global Selloff While Focusing On Imminent Rate Cut The last full week of 2024 started off with a burst of US exceptionalism which helped US equity futures shrug...
Zero Hedge·9mo ago
News Placeholder
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals...
Business Wire·9mo ago
News Placeholder
Edgewise Provides Statement Regarding Companys Relationship with Dr. Han Phan at Rare Disease Research
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the companys relationship with Dr. Han Phan at Rare Disease...
Business Wire·9mo ago
News Placeholder
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on...
Business Wire·9mo ago
News Placeholder
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights. We...
Business Wire·10mo ago

Latest EWTX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.